Gastritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 99 Published: September 30, 2021 Report Code: GMDGDHC13075IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis – Drugs In Development, 2021, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastritis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 2, 5 and 1 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Addpharma Inc

Allakos Inc

CalyGene Biotechnology Inc

Daewon Pharmaceutical Co Ltd

GNT Pharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Kukje Pharmaceutical Industry Co Ltd

Kyowa Kirin Co Ltd

Marinomed Biotech AG

Otsuka Holdings Co Ltd

Recce Pharmaceuticals Ltd

RedHill Biopharma Ltd

Trio Medicines Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastritis – Overview

Gastritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gastritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastritis – Companies Involved in Therapeutics Development

Addpharma Inc

Allakos Inc

CalyGene Biotechnology Inc

Daewon Pharmaceutical Co Ltd

GNT Pharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Kukje Pharmaceutical Industry Co Ltd

Kyowa Kirin Co Ltd

Marinomed Biotech AG

Otsuka Holdings Co Ltd

Recce Pharmaceuticals Ltd

RedHill Biopharma Ltd

Trio Medicines Ltd

Gastritis – Drug Profiles

AAD-2004 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-206 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-20043 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DW-1903 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIP-2101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-2150 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lirentelimab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAM-20101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-07 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rebamipide ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rebamipide SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RECCE-327 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RECCE-435 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastritis – Dormant Projects

Gastritis – Product Development Milestones

Featured News & Press Releases

Jun 07, 2021: Allakos completes patient enrollment in phase 3 eosinophilic gastritis and/or eosinophilic duodenitis and phase 2/3 eosinophilic esophagitis clinical trials of lirentelimab (AK002)

Dec 08, 2020: Rebamipid, which has risen in price, imminent commercialization of domestically developed western-release tablets

Oct 26, 2020: Results from prospective prevalence study indicate that eosinophilic gastritis and eosinophilic duodenitis may be significantly underdiagnosed

Oct 26, 2020: Allakos announces results from a phase 1 study of subcutaneously administered lirentelimab (AK002)

Oct 21, 2020: Anti-Siglec-8 Antibody trial shows promise for treating Eosinophilic gastritis and duodenitis

Oct 21, 2020: Allakos announces publication of results from the phase 2 study of lirentelimab (AK002) in patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

Jun 03, 2020: Allakos initiates patient recruitment for AK002 registrational studies

May 04, 2020: Allakos announces positive interim results from an open-label extension study of Antolimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis

Apr 21, 2020: Allakos announces multiple presentations related to eosinophil and mast cell-driven diseases at the 2020 DDW Annual Meeting

Mar 24, 2020: Allakos announces positive phase 1 results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)

Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gastritis, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Gastritis – Pipeline by Addpharma Inc, 2021

Gastritis – Pipeline by Allakos Inc, 2021

Gastritis – Pipeline by CalyGene Biotechnology Inc, 2021

Gastritis – Pipeline by Daewon Pharmaceutical Co Ltd, 2021

Gastritis – Pipeline by GNT Pharma Co Ltd, 2021

Gastritis – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Gastritis – Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2021

Gastritis – Pipeline by Kyowa Kirin Co Ltd, 2021

Gastritis – Pipeline by Marinomed Biotech AG, 2021

Gastritis – Pipeline by Otsuka Holdings Co Ltd, 2021

Gastritis – Pipeline by Recce Pharmaceuticals Ltd, 2021

Gastritis – Pipeline by RedHill Biopharma Ltd, 2021

Gastritis – Pipeline by Trio Medicines Ltd, 2021

Gastritis – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Gastritis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.